Pharmaceutical company Pfizer has announced a voluntary recall of the pain medication Embeda because of formulation problems, according to a Reuters news report. The recall occurs just weeks after ...

The Food and Drug Administration on Thursday approved Zavzpret, a new nasal spray designed to treat migraines, with the potential to work in just 15 minutes. The drug, which Pfizer acquired when ...

Pfizer has completed its acquisition of pain medication company Icagen in a deal worth almost $50 million, according to a Pfizer press release. Icagen, based in Research Triangle Park, N.C., focuses ...

Vertex Pharmaceuticals claimed in a press release that the medication can be used for many types of moderate-to-severe acute pain and has shown no evidence that it is addictive, like opioids ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients. Doctors share what patients should know about the drug.

The drug is for moderate to severe acute pain. The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe ...

The drug, suzetrigine, received the FDA's official stamp of approval Thursday to be sold as a 50-milligram prescription pill taken every 12 hours, according to a press release.The medication will ...

Pfizer fined $2.3 billion for illegal marketing in off-label drug case. By ABC News. September 2, 2009, 10:15 PM ... such as for pain relief after knee replacement surgery.

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty big deal,” Gupta said. “As you just mentioned, it’s b… ...

A new brain cancer study from Mass General Brigham suggests that gabapentin, a pain-relieving drug, may extend survival in glioblastoma patients, showing promising results.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.